pharmaceutical investing TG Therapeutics Announces Publication of Clinical Data from the Phase 1 First-in-Human Trial of Umbralisib
Results from Vericel’s Positive Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T Presented Today at ACC and Published in The Lancet
EraNova Announces Positive Preliminary Economic Assessment for the Adanac Molybdenum Project: After-Tax NPV of $714.4 Million and 23.5% IRR
